Company Stemline Therapeutics, Inc.
Equities
US85858C1071
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 03-08-07 |
David Gionco
DFI | Director of Finance/CFO | 63 | 14-01-15 |
Jeffrey Levitt
CMP | Compliance Officer | - | 18-02-28 |
Nassir Habboubi
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Kenneth Hoberman
COO | Chief Operating Officer | 59 | 12-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 03-08-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,510,785 | 52,125,679 ( 99.27 %) | 0 | 99.27 % |
Company contact information
Stemline Therapeutics, Inc.
750 Lexington Avenue 11th floor
10022, New York
+646-502-2310
http://www.stemline.comSector
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |